Original Article

You have full text access to this OnlineOpen article

Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia

  1. Merat Karbasian-Esfahani M.D.†,*,
  2. Peter H. Wiernik M.D.,
  3. Yelena Novik M.D.,
  4. Elisabeth Paietta Ph.D.,
  5. Janice P. Dutcher M.D.

Article first published online: 27 JUL 2004

DOI: 10.1002/cncr.20494

Issue

Cancer

Cancer

Volume 101, Issue 6, pages 1414–1419, 15 September 2004

Additional Information

How to Cite

Karbasian-Esfahani, M., Wiernik, P. H., Novik, Y., Paietta, E. and Dutcher, J. P. (2004), Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia. Cancer, 101: 1414–1419. doi: 10.1002/cncr.20494

Author Information

  1. Comprehensive Cancer Center, Our Lady of Mercy Medical Center, New York Medical College, Bronx, New York

  1. †

    Fax: (718) 920-1123

*Our Lady of Mercy Cancer Center, 600 E.233rd Street, Bronx, NY 10466

Publication History

  1. Issue published online: 1 SEP 2004
  2. Article first published online: 27 JUL 2004
  3. Manuscript Accepted: 10 JUN 2004
  4. Manuscript Revised: 4 JUN 2004
  5. Manuscript Received: 1 APR 2004

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (79K)

REFERENCES

  • 1
    Garicia-Manero G, Faderl S, Giles F, et al. A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes. Haematologica. 2002; 87: 804–807.
  • 2
    Giona F, Testi AM, Amadori S, et al. Idarubicin and high dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia. Ann Oncol. 1990; 1: 51–55.
  • 3
    Testi AM, Moleti ML, Giona F, et al. A single high dose of idarubicin combined with high dose ARAC (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University “La Sapienza” of Rome. Haematologica. 1997; 82: 664–667.
  • 4
    Mazza JJ, Leong T, Rowe JM, et al. Treatment of adult patients with acute lymphocytic leukemia in relapse. Leuk Lymphoma. 1996; 20: 317–319.
  • 5
    Abromowitch M, Bowman WP, Ochs J, et al. Etoposide (VP-16) with prednisone and vincristine for the treatment of refractory acute lymphoblastic leukemia. J Clin Oncol. 1985; 3: 789–792.
  • 6
    Krischer J, Land VJ, Divin CI, et al. Evaluation of AMSA in children with acute leukemia: a pediatric oncology group study. Cancer. 1984; 54: 1256–1259.
    Direct Link:
  • 7
    Ryan DH, Brickers JN, Vial RH, et al. Doxorubicin and ifosfamide combination chemotherapy in previously treated acute leukemia in adults: a Southwest Oncology Group pilot study. Cancer Treat Rep. 1980; 64: 869–872.
  • 8
    Herzig BH, Wolff SN, Lazanes HM, et al. High dose cytosine arabinoside therapy for refractory leukemia. Blood. 1983; 62: 361–369.
  • 9
    Weiss MA, Drullinsky P, Maslak P. A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia. Leukemia. 1988; 12: 856–858.
  • 10
    Weiss MA. Treatment of adult patients with relapsed or refractory acute lymphblastic leukemia. Leukemia. 1997; 11 (Suppl. 4): S28–S30.
  • 11
    Carella AM, Pungolino E, Piatti G, et al. Idarubicin in combination with intermediate-dose cytarabine in the treatment of refractory or relapsed acute leukemias. Eur J Haematol. 1989; 43: 309–313.
    Direct Link:
  • 12
    Bernstein MI, Abshire TC, Pollock BH, et al. Idarubicin and cytosine arabinoside reinduction therapy for children with multiple recurrent or refractory acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol. 1997; 19: 68–72.
  • 13
    Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990; 8: 813–819.
  • 14
    Cave H, van der Werff ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer, Childhood Leukemia Cooperative Group. N Engl J Med. 1998; 339: 591–598.
  • 15
    Hoelzer D, Gokbuget N. Diagnosis and treatment of adult acute lymphoblastic leukemia. In: WiernikPH, DutcherJP, GoldmanJ, KyleR, editors. Neoplastic diseases of the blood, 4th edition. Cambridge: Cambridge University Press, 2003: 273–305.
  • 16
    Belaud-Rotureau MA, Durrieu F, Labroille G, et al. Study of apoptosis-related responses of leukemic blast cells to in vitro anthracycline treatment. Leukemia. 2000; 14: 1266–1275.
  • 17
    Wiernik PH, Banks PL, Case DC Jr., et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992; 79: 313–319.
  • 18
    Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 1991; 77: 1666–1674.
  • 19
    Cerososimo RJ. Idarubicin: an anthracycline antineoplastic agent. Clin Pharm. 1992; 11: 152–167.
  • 20
    Creutzig U, Kornholz D, Niemeyer CM, et al. Toxicity and effectiveness of high dose idarubicin during AML induction therapy: results of a pilot study in children. Klin Padiatr. 2002; 212: 163–168.
  • 21
    Barone S, Baer MR, Sait SN, et al. High-dose cytosine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis. Am J Hematol. 2001; 7: 119–124.
    Direct Link:
  • 22
    Flasshove M, Meusers P, Schutte J, et al. Long-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute myeloid leukemia. Ann Hematol. 2000; 79: 533–542.
  • 23
    Creutzig U, Ritter J, Zimmerman M, et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group. Leukemia. 2001; 15: 348–354.
  • 24
    Hartman F, Jacobs G, Gotto H, et al. Cytosine arabinoside, idarubicin and divided dose etoposide for the treatment of acute myeloid leukemia in elderly patients. Leuk Lymphoma. 2001; 42: 347–355.
  • 25
    Giles FJ, Faderl S, Thomas DA, et al. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J Clin Oncol. 2003; 21: 1050–1056.
  • 26
    Alvarado Y, Tsimberidou A, Kantarjian H, et al. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol. 2003; 51: 87–90.
  • 27
    Fulle HH, Hellrigel KP. 4-Demethoxydaunorubicin (idarubicin) in relapsed and refractory acute myeloid leukemia. Haematol Blood Transfus. 1987; 30: 34–35.
  • 28
    Lee ST, Jang JH, Suh HC, et al. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high risk myelodysplastic syndrome. Am J Hematol. 2001; 68: 237–245.
    Direct Link:
  • 29
    Weiss MA, Aliff TB, Tallman MS, et al. A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia. Cancer. 2002; 95: 581–587.
    Direct Link:
  • 30
    Del Principe MI, Del Poeta G, Maurillo L, et al. P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukemia. Br J Haematol. 2003; 121: 730–738.
    Direct Link:
  • 31
    Bassan R, Chiodini B, Lerede T, et al. The role of idarubicin in adult acute lymphoblastic leukemia: from drug resistance studies to clinical application. Leukemia Lymphoma. 1997; 26 (Suppl. 1): 89–97.
  • 32
    Nuessler V, Gieseler F, Zwierzina H, et al. Idarubicin monotherapy in multiply pretreated leukemia patients: response in relation to P glycoprotein expression. Ann Hematol. 1997; 74: 57–64.
  • 33
    Secker-Walker LM, Prentice HG, Durrant J. Cytogenetics adds independent prognostic information in adults with a lymphoblastic leukemia on MRC trial UKALL XA. MRC Adult Leukemia Working Party. Br J Haematol. 1997; 9: 601–610.
    Direct Link:
  • 34
    Paietta E. Immunobiology of acute leukemia In: WiernikPH, DutcherJP, GoldmanJ, KyleR, editors. Neoplastic diseases of the blood, 4th edition. Cambridge: Cambridge University Press, 2003: 194–231.
View Full Article (HTML) Get PDF (79K)